Opendata, web and dolomites

Glucoset

Boronic acid hydrogel sensor for intravascular (arterial) blood glucose monitoring

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Glucoset project word cloud

Explore the words cloud of the Glucoset project. It provides you a very rough idea of what is the project "Glucoset" about.

frequently    critically    diseases    company    intensive    980    ill    blood    hyperglycaemia    icus    central    size    episodes    venous    market    critical    solution    life    infusions    variability    glucose    tip    dangerous    hydrogel    disturbing    consequently    nurses    population    arterial    accuracy    sensibility    addressable    patients    insulin    glucoset    115    micro    equally    direct    physicians    spontaneously    worldwide    advantages    hypoglycaemic    interference    million    wrist    length    turnover    administration    installed    pass    levels    accurate    thin    estimates    125    patient    unexpected    drops    day    position    demand    optical    intravascular    pressure    aging    exposing    time    savings    caused    shaped    volume    measuring    care    least    sensor    introduction    dome    style    total    bed    risk    small    1425    catheters    continuous    exceeding    glycaemia    first    2000    close    stay    needing    monitoring    convenient    incidents    icu    services    estimate    fibres    lives    acute    units    94   

Project "Glucoset" data sheet

The following table provides information about the project.

Coordinator
GLUCOSET AS 

Organization address
address: SLUPPENVEGEN 6
city: TRONDHEIM
postcode: 7037
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Norway [NO]
 Project website http://www.glucoset.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.5. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced manufacturing and processing)
2. H2020-EU.2.1.3. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials)
3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
4. H2020-EU.2.1.2. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-06-01   to  2016-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GLUCOSET AS NO (TRONDHEIM) coordinator 50˙000.00

Map

 Project objective

The problem: Blood glucose levels in critically ill patients require close attention by the physicians and nurses in the intensive care units (ICU) because these patients spontaneously develop hyperglycaemia and increased variability of blood glucose. Unexpected drops in blood glucose are frequently caused by over-administration of insulin – exposing patient´s lives to dangerous hypoglycaemic episodes. These incidents increase the length of stay in ICUs and each bed day in an ICU has large direct costs around €1425.

The solution: GlucoSet is a novel dome-shaped hydrogel sensor that changes its volume and consequently its optical path length in the presence of glucose. The hydrogel tip is built at the end of thin optical fibres (125 µm), which enables GlucoSet to be the only technology small enough to pass through wrist arterial catheters, installed in most (up to 94%) ICU patients, without disturbing the blood pressure monitoring. GlucoSet has the potential to be the first real-time monitoring system for measuring glycaemia from arterial blood, which offer several advantages over central venous access such as higher accuracy and sensibility, less risk of interference from infusions, and much more convenient use.

The market: Critical care services face increasing demand worldwide – more particularly in the EU. With continuous increase in aging population in Europe along with life style related diseases, the number of critically ill patients needing accurate glucose monitoring in the ICUs will certainly rise. GlucoSet AS estimates a total market size of € 980 million per year for the intravascular continuous glucose monitoring, being the company in a strong position to exploit an addressable turnover exceeding € 115 million, five years after market introduction. Equally important, we estimate that the GlucoSet will allow savings of at least €2000 per patient in ICUs.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GLUCOSET" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GLUCOSET" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.5.;H2020-EU.2.1.3.;H2020-EU.2.3.1.;H2020-EU.2.1.2.)

SUPPLEPRINT (2018)

Super Productive Line Printing Inkjet

Read More  

Volumizer (2018)

A natural, non-surgical, and safe facial filler which treats the root cause of facial ageing.

Read More  

STAR (2018)

Safe, Transparent, Active and Reliable mineral sunscreen technology

Read More